This is my fifth UroGen Pharma (NASDAQ: URGN ) article, following 11/2024's "UroGen Pharma: Choice Based On Near-Term High-Value PDUFA" ( High-Value ). In this article, I will again admonish myself for a strong miss in High-Value's “StrongWriting under the pseudonym "out of ignorance", I very much regard investing as a learning process. Investing failures are tuition paid. Investing successes enter the trove of lessons learned. In my Seeking Alpha articles I share my experience from decades of investing and ...